ANSWER: B

Rationale:

COX-1 (cyclooxygenase-1) is constitutively expressed in gastric epithelial cells, mucus-secreting cells, and submucosal blood vessels, where it synthesizes prostaglandin E2 (PGE2) and prostacyclin (PGI2). These prostaglandins simultaneously maintain all four components of the mucosal defense barrier: they stimulate mucus and bicarbonate secretion from surface epithelial cells, maintain mucosal blood flow through vasodilation of submucosal arterioles, inhibit acid secretion via EP3 (prostaglandin E receptor subtype 3) receptors on parietal cells, and promote epithelial restitution after injury. NSAID-mediated COX-1 suppression removes all four of these defenses at once, creating a mucosa vulnerable to injury by luminal acid, bile, and Helicobacter pylori — a systemic prostaglandin-depletion effect rather than a topical chemical injury. This is why even parenterally administered or enteric-coated NSAIDs cause equivalent rates of mucosal injury as standard oral formulations, confirming that the mechanism is prostaglandin-mediated, not topical.

• Option A: Option A is incorrect because topical mucosal contact is not the primary mechanism — parenteral NSAIDs produce equivalent gastropathy, demonstrating that the injury is driven by systemic prostaglandin suppression, not local drug contact.
• Option C: Option C is incorrect because NSAIDs do not inhibit H2 (histamine type 2) receptors; that is the mechanism of H2-receptor antagonists such as ranitidine.
• Option D: Option D is incorrect because NSAID gastropathy is not IgE-mediated; it is a pharmacodynamic consequence of COX-1 inhibition and prostaglandin depletion, not an allergic mast cell reaction.
• Option E: Option E is incorrect because while prostaglandins do influence gastric motility, impaired gastric emptying is not the mechanism of NSAID-induced mucosal damage; the gastropathy occurs independently of motility effects.

ANSWER: D

Rationale:

Proton pump inhibitors (PPIs) are the preferred and best-evidenced gastroprotective agents for patients receiving NSAIDs who have risk factors for GI complications. PPIs suppress gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase proton pump in parietal cells, reducing luminal acidity and protecting the prostaglandin-depleted mucosa from acid injury. Clinical trial data demonstrate that PPIs reduce the relative risk of endoscopic NSAID ulcers by approximately 75%, and they are superior to both H2-receptor antagonists and misoprostol for this indication when adherence and tolerability are considered. This patient has a strong indication for PPI co-therapy given his prior duodenal ulcer and age above 65 — both high-risk factors.

• Option A: Option A is incorrect as a preferred choice because while misoprostol is the only agent that directly replaces mucosal prostaglandin and is effective for NSAID ulcer prevention, its clinical use is severely limited by dose-dependent diarrhea and abdominal cramping that reduce tolerability and adherence; PPIs are preferred in current guidelines.
• Option B: Option B is incorrect because H2-receptor antagonists (H2RAs) are less effective than PPIs for NSAID ulcer prevention; H2RAs reduce endoscopic ulcer rates but are inferior to PPIs in head-to-head comparisons, and H2RA tolerance (tachyphylaxis) develops with continuous use.
• Option C: Option C is incorrect because sucralfate has not been demonstrated to effectively prevent NSAID-associated peptic ulcers; it provides mechanical mucosal coating but does not overcome the prostaglandin-deficiency mechanism driving NSAID gastropathy.
• Option E: Option E is incorrect because enteric-coated NSAIDs do not reduce the risk of NSAID gastropathy; the mechanism is systemic prostaglandin depletion, not local mucosal contact — parenterally administered NSAIDs produce equivalent gastropathy, confirming that coating formulations do not protect against this prostaglandin-mediated injury.

ANSWER: A

Rationale:

Prior peptic ulcer disease or upper GI bleeding is the single strongest validated risk factor for NSAID-associated serious GI complications. A history of a prior ulcer complicated by bleeding — as in this patient — confers the highest risk of any individual factor, increasing the relative risk of a serious GI event by approximately 5-fold compared to patients without this history; a history of prior complicated ulcer (bleeding, perforation) carries an even greater risk than uncomplicated prior ulcer. This risk reflects the structural vulnerability of previously injured mucosa, persistent H. pylori colonization in some patients, and the inability of the prostaglandin-depleted mucosa to adequately repair at previously damaged sites. Recognition of prior GI bleeding as the dominant risk factor is essential for selecting gastroprotective strategy — in such a patient, the combination of celecoxib plus a PPI represents the highest-risk-reduction approach.

• Option B: Option B is incorrect as the answer because while age above 65 is an independent and important GI risk factor, it is not the single strongest predictor; prior GI bleeding carries substantially greater relative risk than age alone.
• Option C: Option C is incorrect as the single greatest risk factor because concurrent anticoagulant use multiplies GI bleeding risk and is clinically important, but as a category of risk it is ranked below prior GI bleeding, which represents the dominant individual predictor of serious GI events.
• Option D: Option D is incorrect because female sex has not been established as an independent risk factor for NSAID-associated GI bleeding; it is not included in validated risk stratification frameworks such as the American College of Gastroenterology guidelines.
• Option E: Option E is incorrect because metformin does not inhibit gastric carbonic anhydrase or impair mucosal bicarbonate secretion; it works primarily by inhibiting hepatic gluconeogenesis via AMP-activated protein kinase (AMPK) pathways and has no established mechanism of NSAID gastropathy potentiation.

ANSWER: C

Rationale:

NSAID gastropathy is a systemic prostaglandin-depletion effect rather than a topical chemical injury. COX-1 (cyclooxygenase-1) is constitutively expressed in gastric mucosal cells and submucosal blood vessels, where it synthesizes PGE2 (prostaglandin E2) and PGI2 (prostacyclin) that maintain mucus secretion, bicarbonate output, mucosal blood flow, and epithelial repair. When an NSAID reaches the systemic circulation — regardless of whether it was given orally, rectally, or intravenously — it inhibits COX-1 in the gastric mucosa via the bloodstream, depleting these prostaglandins and impairing all four defense mechanisms simultaneously. This is confirmed by clinical and endoscopic evidence showing that parenteral NSAIDs, enteric-coated formulations, and rectal suppositories all cause rates of gastric mucosal injury equivalent to standard oral preparations, directly disproving a topical injury mechanism.

• Option A: Option A is incorrect because ketorolac is not significantly secreted into the gastric lumen via biliary excretion; its gastropathy results from systemic COX-1 inhibition in the gastric vasculature and epithelium, not from enterohepatic recirculation into the stomach.
• Option B: Option B is incorrect because NSAIDs do not stimulate vagal acid secretion; acid hypersecretion is not the mechanism of NSAID gastropathy — the primary mechanism is prostaglandin depletion impairing mucosal defense, not increased acid production.
• Option D: Option D is incorrect because while parenteral administration does bypass first-pass metabolism, this does not mean ketorolac achieves higher mucosal COX-1 inhibition than oral dosing; the relevant point is that systemic COX-1 inhibition at therapeutic plasma concentrations is sufficient to impair gastric prostaglandin synthesis regardless of route.
• Option E: Option E is incorrect because there is no mechanism by which circulating NSAIDs are secreted back into the gastric lumen to cause topical injury; this proposed mechanism is physiologically implausible and contradicted by the evidence that parenteral NSAIDs cause equivalent gastropathy.

ANSWER: E

Rationale:

The cardiovascular risk of selective COX-2 inhibitors arises from disruption of the physiological balance between two opposing prostanoids: prostacyclin (PGI2) and thromboxane A2 (TXA2). Vascular endothelial cells synthesize PGI2 predominantly via COX-2; PGI2 inhibits platelet aggregation, promotes vasodilation, and suppresses vascular smooth muscle proliferation. Platelets synthesize TXA2 exclusively via COX-1; TXA2 promotes platelet aggregation, vasoconstriction, and smooth muscle proliferation. Under physiological conditions, these two prostanoids maintain a hemostatic equilibrium. Selective COX-2 inhibition suppresses endothelial PGI2 while leaving platelet COX-1-derived TXA2 completely unaffected. The resulting unopposed TXA2 activity in the context of PGI2 deficiency creates a prothrombotic, vasoconstrictive vascular environment that increases the risk of myocardial infarction (MI), ischemic stroke, and sudden cardiac death. This mechanism was predicted by FitzGerald and colleagues on pharmacological grounds before clinical trial evidence emerged.

• Option A: Option A is incorrect because COX-2 selective inhibitors do not reduce TXA2 synthesis; TXA2 in platelets is synthesized exclusively by COX-1, which COX-2 inhibitors do not suppress. The pharmacological problem is excess TXA2 relative to PGI2, not the reverse.
• Option B: Option B is incorrect because COX-2 inhibitors do not cause QT prolongation through cardiac conduction system prostaglandin depletion; QT prolongation is not a recognized class effect of NSAIDs, and this is not the mechanism of their cardiovascular toxicity.
• Option C: Option C is incorrect because platelets do not express functional COX-2 at levels relevant to TXA2 synthesis; platelet TXA2 is COX-1-derived, and COX-2 selective inhibitors do not impair platelet aggregation.
• Option D: Option D is incorrect because while COX-2 inhibitors do promote renal sodium retention and blood pressure elevation — a real class effect — this mechanism does not typically cause hypertensive emergency and is a secondary contributor rather than the primary driver of the cardiovascular risk signal observed in outcome trials.

ANSWER: B

Rationale:

The VIGOR (Vioxx Gastrointestinal Outcomes Research) trial randomized patients with rheumatoid arthritis (RA) to rofecoxib (a selective COX-2 inhibitor) versus naproxen (a non-selective NSAID), with the primary aim of demonstrating superior GI safety with rofecoxib. VIGOR did demonstrate significantly fewer GI events with rofecoxib, but it also found a 5-fold increase in the rate of myocardial infarction (MI) with rofecoxib compared to naproxen. At the time of publication, the investigators and many reviewers attributed the excess MI risk to a cardioprotective effect of naproxen — based on naproxen's sustained platelet COX-1 inhibition — rather than to intrinsic cardiovascular toxicity of rofecoxib. This interpretation delayed recognition of rofecoxib's cardiovascular harm. Definitive evidence of intrinsic harm came later from the APPROVe trial, which compared rofecoxib to placebo and showed that rofecoxib doubled the rate of serious cardiovascular events compared to placebo.

• Option A: Option A is incorrect because APPROVe — not VIGOR — was the trial that compared rofecoxib to placebo and demonstrated a 2-fold CV event increase; APPROVe studied colorectal polyp prevention, not RA. Additionally, it was rofecoxib — not celecoxib — that was voluntarily withdrawn from the market.
• Option C: Option C is incorrect because VIGOR compared rofecoxib to naproxen, not to placebo; the placebo-controlled demonstration of intrinsic rofecoxib cardiovascular toxicity came from the APPROVe trial, not VIGOR.
• Option D: Option D is incorrect because VIGOR enrolled patients with RA and compared rofecoxib to naproxen, not ibuprofen to naproxen in OA patients; the CNT meta-analysis data on ibuprofen and diclofenac came from a pooled analysis of multiple trials, not from VIGOR.
• Option E: Option E is incorrect because VIGOR was designed as a GI safety trial, not a cardiovascular outcomes trial, and it was not terminated early for cardiovascular benefit; it found increased, not decreased, cardiovascular events with rofecoxib.

ANSWER: D

Rationale:

The APPROVe (Adenomatous Polyp Prevention on Vioxx) trial was the pivotal study that established rofecoxib's cardiovascular harm as an intrinsic drug property. APPROVe was designed to evaluate rofecoxib 25 mg/day versus placebo for the prevention of colorectal adenomas (precancerous polyps of the colon) in patients without prior cardiovascular disease. After approximately 18 months of follow-up, rofecoxib was found to double the rate of serious cardiovascular events (primarily MI and stroke) compared to placebo, providing unequivocal evidence that the cardiovascular risk was an intrinsic pharmacological consequence of rofecoxib — not an artifact of comparison to cardioprotective naproxen as had been suggested in the VIGOR analysis. This definitive placebo-controlled evidence prompted the voluntary market withdrawal of rofecoxib in September 2004.

• Option A: Option A is incorrect because the PRECISION trial evaluated celecoxib versus ibuprofen and naproxen — not a placebo arm — and was specifically designed to assess celecoxib's CV safety relative to two non-selective NSAIDs; it found celecoxib non-inferior but did not resolve the question of intrinsic rofecoxib harm, which had already been established by APPROVe.
• Option B: Option B is incorrect because the CLASS trial was a GI safety trial comparing celecoxib to non-selective NSAIDs, not a placebo-controlled cardiovascular trial; CLASS did not demonstrate that celecoxib doubled cardiovascular events.
• Option C: Option C is incorrect because the CNT meta-analysis did include data on COX-2 inhibitors and confirmed elevated cardiovascular risk with high-dose diclofenac and ibuprofen as well as coxibs; it did not exonerate rofecoxib or conclude that CV risk was unique to non-selective NSAIDs.
• Option E: Option E is incorrect because there was no VIGOR extension comparing rofecoxib to placebo; the critical placebo-controlled evidence came from the separate APPROVe trial, and rofecoxib was withdrawn in 2004 rather than reformulated at a lower dose.

ANSWER: A

Rationale:

Naproxen consistently demonstrates the most favorable cardiovascular profile among commonly used oral NSAIDs in both observational studies and the CNT (Coxib and traditional NSAID Trialists) meta-analysis of over 280 randomized trials. In the CNT meta-analysis, naproxen 1,000 mg/day did not significantly increase major vascular events compared to placebo, while high-dose diclofenac (150 mg/day) and high-dose ibuprofen (2,400 mg/day) each increased major vascular events by approximately one-third. The proposed mechanistic explanation for naproxen's relative safety is that its long plasma half-life of 12 to 17 hours causes sustained platelet COX-1 inhibition with incomplete TXA2 recovery between twice-daily doses, creating an aspirin-like antiplatelet effect that partially offsets the endothelial PGI2 suppression that all NSAIDs share. This partial TXA2 suppression helps maintain a more balanced prostanoid environment. In patients with established cardiovascular disease requiring an NSAID, naproxen is the preferred agent based on this evidence.

• Option B: Option B is incorrect because celecoxib's high COX-2 selectivity — by suppressing endothelial PGI2 without counterbalancing platelet TXA2 — is precisely the mechanism that confers cardiovascular risk; celecoxib carries a class-wide black box warning for cardiovascular risk and should not be used in patients with established cardiovascular disease.
• Option C: Option C is incorrect because indomethacin does not have the most favorable cardiovascular risk profile; it carries significant cardiovascular and renal toxicity and is among the more hazardous NSAIDs in patients with cardiovascular disease.
• Option D: Option D is incorrect because diclofenac at high doses (150 mg/day) increased major vascular events by approximately one-third in the CNT meta-analysis, comparable to ibuprofen and celecoxib; its mixed COX profile does not confer cardiovascular protection.
• Option E: Option E is incorrect because PRECISION compared celecoxib, ibuprofen, and naproxen — all at moderate doses in a high-cardiovascular-risk arthritis population — and found celecoxib non-inferior to the two comparators at those doses; this does not mean high-dose ibuprofen has the same cardiovascular event rate as naproxen in all populations, and ibuprofen at high doses increases cardiovascular events in the CNT analysis.

ANSWER: C

Rationale:

The triple whammy combination of an NSAID, a RAAS (renin-angiotensin-aldosterone system) inhibitor (ACE inhibitor or ARB), and a diuretic causes AKI (acute kidney injury) through additive impairment of the three mechanisms that maintain GFR (glomerular filtration rate) in physiologically stressed patients. First, renal prostaglandins (PGE2 and PGI2) maintain afferent arteriolar dilation in states of reduced renal perfusion pressure; NSAID-mediated COX inhibition removes this vasodilatory buffer, allowing unopposed angiotensin II to constrict the afferent arteriole and reduce GFR. Second, angiotensin II normally constricts the efferent arteriole to maintain glomerular hydrostatic pressure (the force that drives filtration) even when afferent flow falls; ACE inhibitor or ARB therapy blocks this efferent constriction, eliminating the compensatory mechanism. Third, the diuretic causes volume depletion, further reducing renal perfusion pressure. Each component individually impairs a separate compensatory mechanism; together, they eliminate all three safeguards that maintain GFR during hemodynamic stress. In this patient — a CKD patient already at baseline risk — adding ibuprofen to his existing ACE inhibitor and thiazide created the full triple whammy, precipitating severe AKI. Studies have demonstrated markedly elevated risk of AKI hospitalization with this three-drug combination.

• Option A: Option A is incorrect because NSAID-induced renal prostaglandin suppression reduces rather than eliminates sodium excretion, causing sodium and water retention (not natriuresis); the mechanism produces sodium retention, oliguria, and AKI, not hypervolemia from sodium wasting.
• Option B: Option B is incorrect because competitive albumin binding between ibuprofen and lisinopril is not a recognized mechanism of nephrotoxicity; neither drug causes direct tubular injury through this proposed mechanism.
• Option D: Option D is incorrect because ibuprofen does not significantly inhibit OAT-mediated metformin secretion in a clinically relevant way; while there are interactions involving renal OAT transporters, the primary mechanism of AKI in this scenario is the triple whammy hemodynamic mechanism, not metformin accumulation.
• Option E: Option E is incorrect because hydrochlorothiazide is a thiazide diuretic that inhibits the Na-Cl cotransporter in the distal convoluted tubule — not carbonic anhydrase as its primary mechanism — and it does not compete with lisinopril for ACE binding sites; this proposed mechanism is pharmacologically incorrect.

ANSWER: E

Rationale:

Diclofenac carries the clearest and best-characterized hepatotoxicity signal among NSAIDs. It undergoes hepatic metabolism via CYP2C9 (cytochrome P450 2C9) and CYP3A4 (cytochrome P450 3A4) to form a reactive acyl glucuronide metabolite — specifically diclofenac-1-O-acyl glucuronide — that is protein-reactive and capable of forming adducts with hepatocellular proteins, triggering immune-mediated hepatocellular injury in susceptible individuals. Asymptomatic transaminase elevations occur in up to 15% of patients at standard therapeutic doses (75 to 150 mg/day), and elevations exceeding three times the ULN (upper limit of normal) occur in approximately 1 to 3% of patients on prolonged therapy. Clinically significant hepatic injury is uncommon in absolute terms relative to the frequency of diclofenac use, but rare cases of severe drug-induced liver injury (DILI) including acute hepatic failure have been reported. Current guidelines recommend monitoring liver function tests during prolonged diclofenac therapy and discontinuing the drug if transaminases exceed 3× ULN. This patient's ALT of 148 U/L is approximately 2.6× the upper limit of normal, warranting close follow-up and clinical assessment.

• Option A: Option A is incorrect because diclofenac hepatotoxicity is not analogous to acetaminophen; acetaminophen causes predictable, dose-dependent hepatotoxicity via NAPQI (N-acetyl-p-benzoquinone imine) formation at toxic doses, while diclofenac hepatotoxicity is idiosyncratic and immune-mediated, occurring at standard therapeutic doses in susceptible patients.
• Option B: Option B is incorrect because diclofenac does not cause hepatotoxicity by inhibiting UGT enzymes and preventing bilirubin conjugation; its mechanism involves reactive metabolite formation and immune-mediated hepatocellular injury, not direct UGT competitive inhibition.
• Option C: Option C is incorrect because NSAID hepatotoxicity is not a class-wide effect and is not mediated by COX-1 inhibition in Kupffer cells; the prostaglandin-portal endotoxin clearance mechanism is not the established basis of diclofenac hepatotoxicity.
• Option D: Option D is incorrect because diclofenac hepatotoxicity is primarily hepatocellular (transaminase elevation pattern) rather than cholestatic; sulindac — not diclofenac — is more characteristically associated with cholestatic hepatitis, and BSEP inhibition is not the established mechanism for diclofenac-related liver injury.

ANSWER: B

Rationale:

NSAIDs cause hyperkalemia through two intersecting mechanisms. First, renal prostaglandins — particularly PGE2 (prostaglandin E2) and PGI2 (prostacyclin) — stimulate renin secretion from juxtaglomerular cells; NSAID-mediated suppression of these prostaglandins reduces renin release, lowering angiotensin II, which in turn reduces aldosterone secretion from the adrenal cortex. Because aldosterone drives potassium secretion in the cortical collecting duct (by upregulating ENaC for sodium absorption, which creates the electrochemical gradient for potassium exit via ROMK channels), reduced aldosterone levels impair potassium excretion. Second, in patients already taking potassium-retaining agents — in this case, both an ARB (which blocks angiotensin II-stimulated aldosterone) and spironolactone (which blocks the aldosterone receptor directly) — the addition of an NSAID stacks a third layer of RAAS (renin-angiotensin-aldosterone system) suppression on an already aldosterone-deficient state. The result is clinically significant hyperkalemia, particularly in CKD where basal renal potassium excretion capacity is already reduced.

• Option A: Option A is incorrect because NSAIDs do not directly inhibit tubular Na-K-ATPase; their hyperkalemic mechanism is indirect, operating through prostaglandin suppression of renin and the subsequent reduction in aldosterone synthesis — not through direct tubular pump inhibition.
• Option C: Option C is incorrect because naproxen is not a clinically significant CYP3A4 inhibitor; naproxen is metabolized primarily via CYP2C9 and does not meaningfully affect losartan activation, which involves conversion of losartan to its active carboxylic acid metabolite EXP3174 via CYP2C9 and CYP3A4.
• Option D: Option D is incorrect because while NSAIDs do suppress renal prostaglandins, the net effect on potassium balance is to reduce potassium excretion (by reducing aldosterone), not to enhance it; the description in option D inverts the actual direction of the electrolyte effect.
• Option E: Option E is incorrect because immune-mediated interstitial nephritis is an idiosyncratic reaction, not a predictable pharmacodynamic interaction between NSAIDs and ARBs, and it would not selectively cause isolated hyperkalemia without other manifestations of tubular dysfunction within one week of initiation in the absence of allergic features.

ANSWER: D

Rationale:

This patient has AERD (aspirin-exacerbated respiratory disease, also called Samter triad), defined by the clinical triad of asthma, chronic rhinosinusitis with nasal polyposis, and acute respiratory reactions triggered by aspirin or any COX-1-inhibiting NSAID. The pathophysiology involves constitutive overproduction of cysteinyl leukotrienes (LTC4, LTD4, LTE4) in the respiratory mucosa, driven by upregulation of 5-LOX (5-lipoxygenase) and LTC4 synthase. Under basal conditions, PGE2 (prostaglandin E2) — synthesized via COX-1 in the airway epithelium — provides tonic suppression of mast cell and eosinophil activation via EP2 receptor signaling. When any COX-1-inhibiting NSAID is administered, two simultaneous events occur: the baseline PGE2-mediated restraint on mast cells and eosinophils is removed, and arachidonic acid (AA) that would normally be metabolized via the COX pathway is redirected into the 5-LOX pathway (leukotriene shunting), causing an acute surge in cysteinyl leukotrienes that triggers bronchoconstriction, rhinorrhea, and urticaria within 30 to 180 minutes of ingestion. Critically, this reaction occurs with any NSAID that inhibits COX-1 — including ibuprofen and naproxen — because the mechanism is based on COX-1 inhibition, not on a drug-specific structural feature.

• Option A: Option A is incorrect because AERD is not an IgE-mediated allergic reaction; skin prick tests and specific IgE to aspirin or NSAIDs are negative in AERD, and the mechanism is pharmacodynamic (COX-1 inhibition), not immunological (IgE-hapten).
• Option B: Option B is incorrect because AERD does not involve complement activation or immune complex formation; it is a pharmacodynamic intolerance reaction driven by leukotriene shunting, not a serum sickness-like immune complex disease.
• Option C: Option C is incorrect because ibuprofen does not irreversibly acetylate COX-1; irreversible acetylation is unique to aspirin. Ibuprofen reversibly inhibits COX-1 competitively, and the mechanism of AERD does not involve TXA2 deficiency — it involves leukotriene excess from redirected arachidonic acid metabolism.
• Option E: Option E is incorrect because NSAIDs do not inhibit histamine N-methyltransferase; the bronchoconstriction in AERD is mediated by cysteinyl leukotrienes acting on CysLT1 receptors in airway smooth muscle, not by histamine accumulation from impaired enzymatic degradation.

ANSWER: A

Rationale:

Celecoxib is the preferred oral NSAID when an anti-inflammatory agent is required in a patient with confirmed or suspected AERD. Because celecoxib selectively inhibits COX-2 (cyclooxygenase-2) without inhibiting COX-1 (cyclooxygenase-1) at standard therapeutic doses, it does not trigger the two simultaneous events that underlie AERD reactions: it neither removes PGE2-mediated restraint on mast cell and eosinophil activity (which requires COX-1 inhibition in the airway epithelium) nor diverts arachidonic acid into the 5-LOX (5-lipoxygenase) pathway through competitive substrate availability (leukotriene shunting). Clinical experience and challenge studies confirm that celecoxib at standard doses does not precipitate bronchoconstriction in AERD patients. However, introduction should occur under medical supervision because rare cross-reactions to celecoxib have been documented in challenge testing in patients with severe AERD, though these appear uncommon at standard doses.

• Option B: Option B is incorrect because naproxen is a non-selective NSAID that inhibits COX-1; its long half-life does not prevent or attenuate AERD reactions — the mechanism of AERD is not dose-rate dependent, and gradual COX-1 inhibition still removes PGE2 suppression and triggers leukotriene shunting. In fact, this patient had a reaction to naproxen.
• Option C: Option C is incorrect because indomethacin is a potent non-selective COX-1 and COX-2 inhibitor; it does not have a secondary inhibitory effect on 5-LOX, and it would be expected to trigger a severe AERD reaction through the same COX-1 inhibition mechanism as aspirin and ibuprofen.
• Option D: Option D is incorrect because even low OTC doses of ibuprofen are capable of causing AERD reactions in sensitive patients; AERD is not uniformly dose-threshold dependent, and there is no established safe minimum ibuprofen dose for AERD patients.
• Option E: Option E is incorrect because aspirin — even at low doses — triggers AERD reactions in affected patients through irreversible COX-1 acetylation in the respiratory mucosa; aspirin at any dose is contraindicated in AERD unless the patient has undergone formal aspirin desensitization, and TXA2 depletion does not protect against AERD — it has no role in the described feedback mechanism.

ANSWER: C

Rationale:

Aspirin desensitization for AERD is a validated clinical procedure performed in a specialized setting with resuscitation capability. The protocol involves administering incrementally increasing aspirin doses — typically starting at 20 to 40 mg and increasing in a stepwise fashion over hours to days — until a reaction occurs (most commonly rhinorrhea, bronchospasm, or urticaria). The reaction is allowed to resolve with standard medical management, and then aspirin dosing is continued and advanced further. After successful desensitization, the patient tolerates aspirin and all other NSAIDs through a mechanism that involves sustained downregulation of the cysteinyl leukotriene pathway — though the precise molecular mechanism is not fully characterized. Critically, this tolerance is not permanent: if daily aspirin is held for more than 72 hours, the tolerance dissipates and the patient reverts to full AERD reactivity. For this patient with coronary artery disease requiring antiplatelet therapy, aspirin desensitization is appropriate — it achieves both the cardiovascular indication (daily aspirin) and, as a documented clinical benefit, reduces nasal polyp burden, improves olfaction, and decreases sinus infection frequency with long-term daily aspirin therapy after desensitization.

• Option A: Option A is incorrect because desensitization does not involve a single large dose or intentional induction of a severe reaction, and it does not permanently eliminate AERD reactivity for years without continued aspirin; tolerance is maintained only by uninterrupted daily aspirin dosing.
• Option B: Option B is incorrect because AERD is not an IgE-mediated reaction and does not require omalizumab pretreatment for desensitization; aspirin desensitization works through a pharmacodynamic leukotriene pathway mechanism, not through IgE suppression.
• Option D: Option D is incorrect because aspirin desensitization does not permanently downregulate LTC4 synthase expression; the tolerance is pharmacodynamic and depends on continuous daily aspirin exposure — it dissipates rapidly when aspirin is stopped, confirming that ongoing drug exposure is necessary to maintain the suppressed leukotriene state.
• Option E: Option E is incorrect because the maintenance of post-desensitization tolerance is achieved by continuous daily aspirin dosing, not by inhaled corticosteroids; while inhaled corticosteroids are part of asthma management in AERD patients, they do not maintain NSAID tolerance in the absence of continued aspirin exposure.

ANSWER: E

Rationale:

The NSAID-anticoagulant interaction is primarily pharmacodynamic in nature and applies to all anticoagulant classes, including DOACs (direct oral anticoagulants). NSAIDs contribute to the interaction through two synergistic mechanisms: first, by inhibiting COX-1 (cyclooxygenase-1)-dependent TXA2 (thromboxane A2) synthesis in platelets, impairing platelet activation and reducing the platelet component of primary hemostasis; second, by causing GI (gastrointestinal) mucosal erosions and ulcerations that create bleeding sites where the anticoagulant's impaired secondary hemostasis cannot adequately compensate. The combined effect is a 2 to 4-fold increase in absolute GI bleeding risk compared to the anticoagulant alone. For standard NSAIDs and DOACs, there are no clinically significant pharmacokinetic interactions — DOACs are not substantially metabolized by or transported through pathways regulated by standard NSAIDs, making the interaction purely pharmacodynamic. This combination should be avoided whenever possible; when co-prescription is unavoidable, PPI (proton pump inhibitor) gastroprotection and the shortest necessary NSAID duration are mandatory.

• Option A: Option A is incorrect because standard NSAIDs and DOACs do not compete significantly for albumin binding sites in a clinically relevant way; the NSAID-anticoagulant interaction is pharmacodynamic, not based on albumin displacement. DOACs vary in protein binding (rivaroxaban ~92-95%, dabigatran ~35%), but albumin displacement is not the mechanism of their interaction with NSAIDs.
• Option B: Option B is incorrect because NSAIDs are not clinically significant P-glycoprotein inhibitors and do not substantially increase DOAC bioavailability through intestinal P-gp inhibition; this is not a recognized mechanism of the NSAID-DOAC interaction.
• Option C: Option C is incorrect because NSAIDs are not CYP3A4 inducers; they do not accelerate rivaroxaban metabolism or reduce DOAC plasma concentrations. The interaction is additive pharmacodynamic bleeding risk, not pharmacokinetic reduction of anticoagulant levels.
• Option D: Option D is incorrect because the pharmacodynamic GI bleeding interaction applies equally to all DOAC classes regardless of their specific anticoagulant mechanism — it does not spare factor Xa inhibitors; the mechanism (mucosal erosion plus impaired platelet hemostasis) is DOAC-class independent.

ANSWER: B

Rationale:

The SSRI-NSAID interaction that increases upper GI bleeding risk is a pharmacodynamic interaction involving concurrent suppression of two independent platelet activation pathways. Serotonin stored in platelets contributes to platelet activation and aggregation through 5-HT2A (serotonin type 2A) receptor signaling; when activated platelets release serotonin, it amplifies the platelet aggregation response. SSRIs block SERT (serotonin reuptake transporter) on the platelet membrane — the mechanism by which platelets normally take up serotonin from the plasma — and since platelets cannot synthesize serotonin de novo, SSRI use progressively depletes platelet serotonin stores, impairing serotonin-dependent platelet activation. NSAIDs simultaneously impair COX-1-dependent TXA2 synthesis, suppressing a second, mechanistically independent platelet activation pathway. The concurrent suppression of both TXA2 and platelet serotonin pathways produces additive platelet dysfunction beyond that attributable to either agent alone, combined with NSAID-induced mucosal erosion providing a GI bleeding site. Epidemiological studies demonstrate a 3 to 15-fold increase in upper GI bleeding risk with the SSRI-NSAID combination compared to either agent alone, and this risk is substantially reduced by PPI co-therapy.

• Option A: Option A is incorrect because while sertraline is a CYP2C9 inhibitor, its inhibition of ibuprofen metabolism is not clinically significant enough to produce 3- to 4-fold ibuprofen plasma level increases; the primary mechanism of the SSRI-NSAID bleeding interaction is pharmacodynamic (dual platelet activation suppression), not pharmacokinetic.
• Option C: Option C is incorrect because SSRIs do not directly inhibit COX enzymes; the mechanism of sertraline's contribution to GI bleeding risk is through platelet serotonin depletion via SERT blockade, not direct prostaglandin synthase inhibition.
• Option D: Option D is incorrect because SSRIs do not stimulate gastric acid secretion via 5-HT3 receptors on ECL cells; if anything, SSRIs may reduce gastric acid secretion modestly through serotonin effects on gastric motility, and increased acid secretion is not the mechanism of the SSRI-NSAID bleeding interaction.
• Option E: Option E is incorrect because competitive albumin displacement between sertraline and ibuprofen is not a clinically significant pharmacokinetic interaction; the documented interaction is pharmacodynamic, mediated by dual platelet activation suppression, not by albumin binding competition raising free drug concentrations.

ANSWER: A

Rationale:

Lithium is an alkali metal ion that is renally cleared and handled in the kidney in a manner that partially parallels sodium handling. Lithium is filtered at the glomerulus and approximately 60 to 80% is reabsorbed in the proximal tubule alongside sodium; the degree of proximal tubular lithium reabsorption varies with the rate of sodium reabsorption in that segment. When NSAIDs suppress renal prostaglandins — particularly PGE2 and PGI2 — they reduce renal blood flow and GFR modestly, while simultaneously enhancing sodium reabsorption in the proximal tubule and other nephron segments (because prostaglandins normally oppose sodium reabsorption). The increased sodium reabsorption drives parallel lithium reabsorption, reducing renal lithium clearance and raising steady-state plasma lithium concentrations. The magnitude of the increase is 10 to 60%, varying by NSAID agent — indomethacin produces the largest effect, while sulindac (which has renal prostaglandin-sparing properties due to its active sulfide metabolite being reconverted to an inactive sulfone in the kidney) shows relatively less effect, though it does not eliminate the interaction. Because lithium has a narrow therapeutic index (toxic above 1.5 mEq/L), even a 30% increase from a baseline level of 0.8 mEq/L could push the level to 1.04 mEq/L, and larger increases can cause toxicity (coarse tremor, confusion, ataxia, cardiac arrhythmias). Serum lithium levels should be checked within 5 to 7 days of initiating or changing NSAID therapy and again at NSAID cessation.

• Option B: Option B is incorrect because lithium is not metabolized by hepatic CYP enzymes; lithium is not organic and has no hepatic metabolism — it is eliminated exclusively by renal excretion as the unchanged ion, making CYP2D6 inhibition irrelevant to lithium pharmacokinetics.
• Option C: Option C is incorrect because lithium renal elimination does not primarily depend on OAT-mediated active secretion; the dominant mechanism of lithium clearance is glomerular filtration with variable tubular reabsorption alongside sodium, not active secretion via OAT transporters.
• Option D: Option D is incorrect because aquaporin-2 activation concentrates tubular fluid but does not meaningfully alter lithium reabsorption in the collecting duct; lithium handling is predominantly a proximal tubular phenomenon tied to sodium reabsorption, and NSAID effects on AQP2 expression are not the mechanism of the lithium interaction.
• Option E: Option E is incorrect because lithium is not hepatically distributed in a pharmacokinetically relevant way — it is a small inorganic cation that distributes via the systemic circulation; the concept of NSAID-induced changes in hepatic blood flow prolonging lithium half-life through hepatic distribution kinetics is not a recognized or physiologically plausible mechanism.

ANSWER: D

Rationale:

The NSAID-methotrexate (MTX) interaction is dose-dependent and clinically critical at the high doses used in oncology (greater than 50 to 100 mg/m² per cycle). NSAIDs reduce renal MTX excretion through two complementary mechanisms. First, competitive inhibition of renal OAT (organic anion transporter) proteins — particularly OAT1 and OAT3 — in the proximal tubular epithelium: these transporters actively secrete MTX from the peritubular capillaries into the tubular lumen, which represents a major route of MTX renal clearance. NSAIDs, which are also OAT substrates, competitively inhibit this secretion, reducing tubular MTX excretion and raising plasma MTX concentrations. Second, reduced renal prostaglandin synthesis causes afferent arteriolar constriction, decreasing GFR (glomerular filtration rate) and renal blood flow, which further reduces filtered MTX load and prolongs its systemic exposure. The combined effect is prolonged, elevated MTX plasma concentrations that cause severe myelosuppression (bone marrow suppression leading to neutropenia, thrombocytopenia), mucositis, and nephrotoxicity through extended inhibition of dihydrofolate reductase (DHFR) in rapidly dividing cells throughout the body. NSAIDs should not be used during or within 24 hours of high-dose MTX infusions. At low weekly rheumatology doses (7.5 to 25 mg/week), the interaction is clinically less severe but warrants caution, with some guidelines recommending withholding NSAIDs around the weekly dose at higher rheumatology doses.

• Option A: Option A is incorrect because methotrexate undergoes minimal hepatic CYP2C8-mediated oxidation; MTX is primarily eliminated unchanged by the kidney through glomerular filtration and active tubular secretion, not through hepatic oxidative metabolism.
• Option B: Option B is incorrect because ibuprofen does not bind to DHFR and does not compete with methotrexate for the DHFR active site; NSAIDs do not inhibit the folate synthesis pathway through enzyme binding.
• Option C: Option C is incorrect because ibuprofen does not induce MRP2 expression through a prostaglandin-nuclear receptor pathway; this is not a recognized mechanism of NSAID-MTX interaction, and the pharmacological claim is not supported by established evidence.
• Option E: Option E is incorrect because while protein displacement can transiently raise free drug concentrations, this mechanism is generally not clinically significant for drugs with large volumes of distribution like methotrexate at chemotherapy doses; the primary clinically meaningful mechanism of NSAID-MTX toxicity is impaired renal MTX clearance through OAT inhibition and reduced GFR, not protein displacement.

ANSWER: C

Rationale:

The ductus arteriosus (DA) is a fetal vascular channel connecting the pulmonary artery to the descending aorta that allows blood to bypass the non-ventilated fetal lungs in utero. Patency of the DA in fetal life is actively maintained by locally produced PGE2 (prostaglandin E2) acting on EP4 (prostaglandin E receptor subtype 4) receptors on ductal smooth muscle, causing vasodilation and keeping the channel open. Normal postnatal DA closure occurs through increased oxygen tension and declining circulating prostaglandins after the placenta is delivered. When NSAIDs are administered in the third trimester — particularly from 28 weeks gestation onward — COX (cyclooxygenase) inhibition suppresses fetal ductal PGE2, causing premature constriction or closure of the ductus arteriosus. This forces the entire right ventricular output through the high-resistance pulmonary circulation, causing right ventricular pressure overload that can progress to fetal hydrops (a severe condition of fluid accumulation in fetal body cavities including the pericardium, peritoneum, and pleural space) and potentially fetal death. For these reasons, NSAIDs are strongly contraindicated in the third trimester; acetaminophen remains the preferred analgesic.

• Option A: Option A is incorrect because NSAID teratotoxicity in the third trimester is not mediated through bilirubin conjugation failure; fetal hyperbilirubinemia is associated with hemolytic conditions, ABO/Rh incompatibility, and G6PD deficiency — not with NSAID-induced COX inhibition in the fetal liver.
• Option B: Option B is incorrect because NSAIDs do not suppress fetal cortisol production through adrenal prostaglandin inhibition; neonatal adrenal insufficiency is not a recognized mechanism of NSAID fetal toxicity in the third trimester.
• Option D: Option D is incorrect because fetal renal vulnerability to NSAIDs persists in the third trimester, not exclusively in earlier trimesters; the FDA Drug Safety Communication regarding NSAID use from 20 weeks applies through all remaining gestational weeks, and fetal renal maturation does not render NSAIDs safe.
• Option E: Option E is incorrect because while NSAIDs can prolong pregnancy by reducing uterine prostaglandin-mediated contractions (this is actually the basis of using indomethacin as a tocolytic, an agent that stops preterm labor, earlier in pregnancy), the primary concern with third-trimester NSAID use is ductal constriction, not preterm labor induction through COX-2 upregulation.

ANSWER: E

Rationale:

The American Geriatrics Society (AGS) Beers Criteria designates all oral non-selective NSAIDs as potentially inappropriate medications (PIMs) in adults aged 65 and older, recommending avoidance unless alternative treatments are ineffective and the patient can take a gastroprotective agent concomitantly. Several converging factors make elderly patients particularly vulnerable to NSAID toxicity: renal reserve declines with age even in the absence of diagnosed CKD (serum creatinine alone is an insensitive indicator in elderly patients with reduced muscle mass), gastric mucosal regenerative capacity decreases, polypharmacy increases the probability of dangerous combinations (triple whammy, anticoagulant co-prescription), and the prevalence of H. pylori is higher. Indomethacin is specifically highlighted as among the most problematic NSAIDs in elderly patients because it is one of the most lipid-soluble and CNS-penetrant NSAIDs in clinical use, with well-documented CNS adverse effects including confusion, dizziness, and somnolence that are substantially more pronounced in elderly patients and can precipitate falls with serious consequences. When an NSAID is needed for localized musculoskeletal pain in an elderly patient, topical diclofenac gel (1%) provides clinically effective analgesia with minimal systemic absorption and substantially lower GI, cardiovascular, and renal risk compared to oral formulations.

• Option A: Option A is incorrect because indomethacin is not the preferred NSAID in elderly patients — it is specifically among the NSAIDs the Beers Criteria most strongly advises against; indomethacin does not provide equivalent cardiovascular protection to aspirin, and its COX-1 inhibition is reversible rather than irreversible (unlike aspirin's irreversible platelet COX-1 acetylation).
• Option B: Option B is incorrect because the Beers Criteria does not exempt indomethacin; indomethacin is specifically called out as one of the most problematic NSAIDs for elderly patients due to its CNS toxicity profile, and rapid onset does not meaningfully reduce cumulative toxicity risk in chronic pain management.
• Option C: Option C is incorrect because age above 65 is itself an independent validated risk factor for NSAID-associated GI, renal, and cardiovascular complications, regardless of additional comorbidities; the Beers Criteria applies to all adults over 65, not only those with additional specific risk factors.
• Option D: Option D is incorrect because topical diclofenac gel produces substantially lower systemic absorption than oral formulations — systemic bioavailability from topical gel is approximately 6 to 10% of an equivalent oral dose — and is specifically recommended as a preferred strategy in elderly patients with localized OA pain who have high systemic risk from oral NSAIDs.

ANSWER: B

Rationale:

This question illustrates a critical clinical principle: serum creatinine is an unreliable sole indicator of renal function in patients with reduced muscle mass, including elderly, cachectic, or malnourished patients, because creatinine is generated by muscle creatine metabolism. A cachectic patient with diabetic nephropathy may have an eGFR of 25 to 35 mL/min/1.73m² despite a serum creatinine that appears "normal" by reference range, because low muscle mass generates little creatinine even when GFR is markedly reduced. The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, which incorporates age, sex, and creatinine, provides a far more accurate eGFR estimate in such patients. NSAIDs should be avoided in patients with eGFR below 30 mL/min/1.73m² (CKD stage G4 or G5) entirely, and used with caution and close monitoring of renal function, blood pressure, and electrolytes in patients with eGFR 30 to 60 mL/min/1.73m² (CKD stage G3). In patients with diabetic nephropathy, the risks are amplified by the proteinuric nephropathy's underlying vulnerability to hemodynamic insults.

• Option A: Option A is incorrect because a "normal" serum creatinine in a cachectic elderly patient cannot be assumed to reflect normal GFR; in patients with reduced muscle mass, creatinine generation is low and serum creatinine remains within the laboratory reference range even when GFR is severely reduced. EGfR calculation is mandatory in this population before prescribing nephrotoxic agents.
• Option C: Option C is incorrect because NSAID-induced GFR reduction in patients with CKD is not therapeutically beneficial; the hemodynamic AKI risk in CKD patients is well established, and NSAIDs can accelerate CKD progression through both hemodynamic and direct tubular mechanisms. Hyperfiltration-induced glomerular injury is managed with RAAS inhibitors, not NSAIDs.
• Option D: Option D is incorrect because there is no established "50% dose reduction" protocol for NSAIDs in patients with mildly elevated creatinine; half-dose NSAIDs still suppress renal prostaglandins and can still precipitate AKI in susceptible patients — the evidence-based approach is avoidance below eGFR 30 and cautious short-term use with monitoring between 30 and 60.
• Option E: Option E is incorrect because NSAIDs are not contraindicated in all patients with diabetes regardless of renal function; diabetic autonomic neuropathy does not constitutively upregulate renal prostaglandins to a degree that makes NSAID use invariably hazardous at normal GFR levels, and this proposed mechanism is not physiologically established.

ANSWER: A

Rationale:

Patients with hepatic cirrhosis and portal hypertension present a high-risk prescribing context for NSAIDs through multiple converging mechanisms. In cirrhosis, splanchnic vasodilation — driven by increased nitric oxide and other vasodilators — causes effective arterial underfilling. The body compensates by markedly activating the RAAS (renin-angiotensin-aldosterone system) and sympathetic nervous system to maintain systemic blood pressure, producing intense renal vasoconstriction via angiotensin II and catecholamines. In this compensated but fragile state, renal perfusion is heavily dependent on locally produced prostaglandins (PGE2 and PGI2) that dilate the afferent arteriole and buffer the vasoconstrictive stimulus. NSAID-mediated suppression of these renal prostaglandins removes the vasodilatory protection, allowing unopposed vasoconstriction to reduce GFR precipitously, causing AKI and potentially triggering hepatorenal syndrome (a severe form of progressive renal failure in cirrhosis). Additional risks include amplified GI bleeding risk (cirrhotic patients have esophageal varices, portal hypertensive gastropathy, and reduced mucosal prostaglandins) and worsened coagulopathy (platelet dysfunction compounds the cirrhosis-associated coagulation factor deficit). NSAIDs are generally contraindicated in Child-Pugh B or C cirrhosis. Acetaminophen at reduced doses — up to 2 g/day in patients with active heavy alcohol use or advanced cirrhosis — is generally safer than NSAIDs because it does not impair renal prostaglandins, does not cause GI ulceration, and its hepatotoxicity at these reduced doses is low in stable cirrhosis.

• Option B: Option B is incorrect because while hepatic metabolism of NSAIDs may be reduced in advanced cirrhosis, this is not the primary reason NSAIDs are contraindicated; the critical mechanism is prostaglandin-dependent renal perfusion and GI mucosal vulnerability, not extreme pharmacokinetic drug accumulation from CYP3A4 impairment alone.
• Option C: Option C is incorrect because NSAIDs do not cause hepatic encephalopathy through direct cerebral COX-2 inhibition in astrocytes; NSAID-associated CNS effects (confusion, dizziness) are seen with highly lipid-soluble agents like indomethacin in elderly patients, not through ammonia-independent astrocyte glutamate mechanism in cirrhosis.
• Option D: Option D is incorrect because the assertion that Child-Pugh A patients have equivalent NSAID risk to patients without liver disease overstates the safety — Child-Pugh A patients should still use NSAIDs with extreme caution and close monitoring, and the statement that prostaglandin synthesis is "fully intact" in Child-Pugh A cirrhosis is an oversimplification that could lead to unsafe prescribing.
• Option E: Option E is incorrect because acetaminophen is not absolutely contraindicated in all patients with hepatic cirrhosis; at reduced doses (maximum 2 g/day in patients with active alcohol use or advanced cirrhosis), acetaminophen is generally considered safer than NSAIDs and is recommended as the preferred analgesic in this population by gastroenterology and hepatology guidelines.